News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
21,254 Results
Type
Article (1762)
Company Profile (19)
Press Release (19473)
Section
Business (7096)
Career Advice (24)
Deals (1035)
Drug Delivery (3)
Drug Development (3686)
Employer Resources (3)
FDA (346)
Job Trends (403)
News (11384)
Policy (708)
Tag
Academia (124)
Adcomms (3)
Allergies (5)
Alliances (1930)
ALS (1)
Alzheimer's disease (27)
Antibody-drug conjugate (ADC) (10)
Approvals (344)
Artificial intelligence (7)
Bankruptcy (7)
Best Places to Work (325)
BIOSECURE Act (5)
Biosimilars (1)
Biotechnology (15)
Bladder cancer (1)
Brain cancer (1)
Cancer (88)
Cardiovascular disease (7)
Career advice (17)
CAR-T (10)
Cell therapy (45)
Clinical research (2720)
Collaboration (47)
Compensation (25)
COVID-19 (414)
CRISPR (4)
C-suite (26)
Cystic fibrosis (7)
Data (89)
Depression (1)
Diabetes (4)
Diagnostics (172)
Drug discovery (3)
Drug pricing (2)
Duchenne muscular dystrophy (2)
Earnings (2090)
Editorial (2)
Employer resources (3)
Events (3315)
Executive appointments (57)
FDA (398)
Funding (48)
Gene editing (8)
Gene therapy (30)
GLP-1 (25)
Government (172)
Guidances (4)
Healthcare (592)
Immunology and inflammation (5)
Infectious disease (422)
Inflammatory bowel disease (8)
Influenza (1)
Intellectual property (4)
Interviews (3)
IPO (535)
IRA (1)
Job creations (88)
Job search strategy (17)
Kidney cancer (1)
Labor market (4)
Layoffs (20)
Legal (96)
Liver cancer (3)
Lung cancer (13)
Lymphoma (13)
Machine learning (1)
Management (2)
Manufacturing (15)
MASH (3)
Medical device (143)
Medtech (143)
Mergers & acquisitions (517)
Metabolic disorders (15)
Neurodegenerative disease (5)
Neuropsychiatric disorders (2)
Neuroscience (45)
NextGen: Class of 2025 (177)
Non-profit (55)
Now hiring (1)
Obesity (7)
Opinion (6)
Ovarian cancer (5)
Pain (7)
Pancreatic cancer (1)
Parkinson's disease (4)
Patents (11)
Patient recruitment (4)
People (2825)
Pharmacy benefit managers (1)
Phase I (1137)
Phase II (1321)
Phase III (846)
Pipeline (53)
Policy (11)
Postmarket research (55)
Preclinical (390)
Press Release (1)
Prostate cancer (4)
Radiopharmaceuticals (11)
Rare diseases (22)
Real estate (190)
Recruiting (1)
Regulatory (544)
Reports (6)
Research institute (130)
Resumes & cover letters (3)
RSV (5)
Schizophrenia (4)
Series A (13)
Series B (5)
Service/supplier (1)
Sickle cell disease (1)
Special edition (2)
Spinal muscular atrophy (5)
Sponsored (2)
Startups (182)
Supply chain (2)
Tariffs (3)
Vaccines (65)
Weight loss (3)
Date
Today (14)
Last 7 days (37)
Last 30 days (131)
Last 365 days (1320)
2025 (471)
2024 (1467)
2023 (1760)
2022 (2381)
2021 (2405)
2020 (1939)
2019 (1255)
2018 (886)
2017 (1098)
2016 (941)
2015 (1119)
2014 (796)
2013 (659)
2012 (605)
2011 (622)
2010 (529)
Location
Africa (27)
Alabama (1)
Asia (1321)
Australia (145)
California (335)
Canada (86)
China (20)
Colorado (3)
Connecticut (14)
Delaware (5)
Europe (5530)
Florida (41)
Georgia (2)
Idaho (1)
Illinois (8)
India (1)
Indiana (4)
Japan (7)
Maryland (86)
Massachusetts (172)
Michigan (4)
Minnesota (8)
New Jersey (55)
New Mexico (1)
New York (32)
North Carolina (19)
Northern California (129)
Ohio (8)
Oklahoma (1)
Oregon (1)
Pennsylvania (93)
Puerto Rico (1)
South America (24)
Southern California (121)
Texas (27)
United States (916)
Utah (14)
Virginia (1)
Washington D.C. (2)
Washington State (14)
Wisconsin (1)
21,254 Results for "oxford biotherapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Antibody-drug conjugate (ADC)
Roche Ups ADC Bet With $1B in Biobucks for Oxford BioTherapeutics
Roche’s up to $1 billion investment will provide access to Oxford BioTherapeutics’ antibody-drug conjugate platform for undisclosed cancer targets.
March 19, 2025
·
1 min read
·
Tristan Manalac
Press Releases
Oxford BioTherapeutics Enters into a Strategic Collaboration with Roche to Discover Novel Targets for Antibody-Based Therapeutics for the Treatment of Cancer
March 19, 2025
·
3 min read
Press Releases
Oxford BioTherapeutics to Present at World ADC Conference 2024
October 31, 2024
·
3 min read
Press Releases
Boehringer Ingelheim Acquires Fourth License for the Development of Novel Antibody Based Cancer Treatments from Oxford BioTherapeutics
January 9, 2025
·
3 min read
Oxford BioTherapeutics Announces Launch of Enhanced Discovery Platform, OGAP®-Verify, at World ADC Conference 2024
Oxford BioTherapeutics announces significant technological advances to its drug discovery platform OGAP® with a new version to be launched at the 14th Annual World ADC Conference in London named OGAP®-Verify.
March 7, 2024
·
6 min read
Press Releases
Oxford-Harrington Rare Disease Centre Appoints Majid Jafar to its Advisory Council
April 30, 2025
·
7 min read
Press Releases
Oxford Nanopore Expands Compatible Products Programme and Strengthens Multi-Omics Ecosystem
April 14, 2025
·
3 min read
Press Releases
Cepheid and Oxford Nanopore Technologies Partner to Advance Automated Sequencing-Based Solutions
April 9, 2025
·
4 min read
Collaboration
Boehringer Ingelheim Expands Cancer Pipeline With Back-to-Back Antibody Deals
On Thursday, Boehringer Ingelheim announced a partnership with Synaffix to advance antibody-drug conjugates and exercised its fourth license option under a 2013 collaboration with Oxford BioTherapeutics.
January 10, 2025
·
2 min read
·
Tristan Manalac
Drug Development
Oxford BioTherapeutics Announces First Patient Dosed with OBT076 in Phase 1b Trial in Adenoid Cystic Carcinomas of the Head and Neck
Oxford BioTherapeutics announces that the first patient has been dosed in a Phase 1b trial investigating OBT’s lead candidate, OBT076, in patients with Adenoid Cystic Carcinoma of the head and neck.
January 18, 2024
·
5 min read
1 of 2,126
Next
